跳至主要内容
临床试验/NCT01431352
NCT01431352Unknown不适用

The Effects of Chinese Herbal Medicine and Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome:A Double-blind Randomized Controlled Trial

Heilongjiang University of Chinese Medicine18 个研究点 分布在 1 个国家目标入组 420 人开始时间: 2009年9月最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
420
试验地点
18
主要终点
Live birth rate

研究概览

简要总结

This is a multicenter double-blind randomized controlled trial. A total of 420 anovulatory Chinese women with PCOS will be recruited, and the randomization will be stratified by each participating site. Participants will be randomized into one of the two treatment arms: letrozole and CHMG or letrozole and CHMG placebo. CHMG or its placebo will be taken twice a day for up to six months. Letrozole (2.5 mg daily) was given on days 3-7 of the menstrual cycle after a spontaneous period or withdrawal bleeding, and the dose will be increased to 5.0 mg daily during the last three months for non-pregnant women in both groups.The aim of the present study is to determine the efficacy of combined treatment with letrozole and CHMG on improving live birth rates in infertile Chinese women with PCOS. Our hypothesis is that the combination of letrozole and CHMG is more likely to increase the ovulation rate and decrease the miscarriage rate and result in a higher live birth rate in PCOS women than letrozole alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Letrozole+ Chinese herbal medicine granules placebo

Placebo Comparator

干预措施: Letrozole (Drug)

Letrozole+ Chinese herbal medicine granules

Experimental

干预措施: Letrozole (Drug)

Letrozole+ Chinese herbal medicine granules

Experimental

干预措施: Chinese herbal medicine granules or Chinese herbal medicine granules placebo (Drug)

结局指标

主要结局

Live birth rate

时间窗: Up to 2 years

次要结局

  • Ovulation rate(Up to 1 year)
  • Miscarriage rate(Up to 1 year)
  • Change in hormonal profile(Up to 1 year)
  • Change in metabolic profile(Up to 1 year)
  • Change in physical measurements(Up to 1 year)
  • Birth defects(Up to 1 year)
  • Pregnancy complications(Up to 1 year)
  • Safety parameters(Up to 1 year)
  • Side effect profile(Up to 1 year)

研究者

发起方
Heilongjiang University of Chinese Medicine
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiaoke Wu

Professor and Chairman Dept Obs & Gyn, First Affiliated Hospital

Heilongjiang University of Chinese Medicine

研究点 (18)

Loading locations...

相似试验